相关实验视频

Updated: Apr 28, 2026

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

根据治疗方法评估PFAPA患者的发作频率

Furkan Kalayci¹, Metin Yigit¹, Aylin Irmak Kuruc¹

¹Department of Pediatrics, Ankara City Hospital, Ankara, Turkey.

Journal of paediatrics and child health

|December 18, 2024

概括

桃切除术和菌素显著降低周期性发烧,口腔炎,喉炎和腺炎 (PFAPA) 发作,而重复使用皮质类固醇会增加发作频率. 桃体切除术为PFAPA综合征提供了优越的长期控制,相比于胆固醇.

科学领域:

儿科风湿病学儿科风湿病学
免疫学免疫学免疫学
遗传学是一个遗传学.

背景情况:

周期性发烧,口腔炎,喉炎和腺炎 (PFAPA) 综合征是儿童常见的自身炎症性疾病.
它的特点是经常出现发烧,口腔,喉炎和宫腺炎.
目前的治疗策略包括皮质类固醇,菌素和桃体切除术,有效性各不相同.

研究的目的:

为了呈现诊断为PFAPA综合征的患者的临床特征.
为了比较皮质类固醇治疗,菌素预防和桃体切除术在控制PFAPA攻击频率方面的有效性.

主要方法:

在2017年至2021年期间,对195名被诊断患有PFAPA综合征的患者进行了回顾性分析.
患者被分为未经治疗的,皮质类固醇,胆固醇和桃体切除组.
记录和分析了人口统计数据,临床特征,实验室发现和治疗结果.

主要成果:

两组之间没有观察到治疗前攻击频率的显著差异.
与治疗前期相比,桃体切除术和粉素都显著降低了PFAPA攻击频率 (p < 0.001).
重复使用皮质类固醇 (≥3次发作) 与发作频率增加有关 (p < 0.0001),而桃体切除术显示发作减少的幅度大于胆固醇 (p < 0.001).

结论:

皮质类固醇对于急性发作管理是有效的,但它们的反复使用可能会加剧PFAPA.
在大多数PFAPA患者中,素预防有效降低了发作频率.
桃体切除术为PFAPA综合征提供了很高的疾病控制率,在本研究中显示出比桃素更高的疗效.

关键词:

这就是PFAPAPA.科尔奇辛 (Colchicine) 是一种可怕的药物.这是一种皮质类固醇.进行桃体切除术 (tonsillectomy).

更多相关视频

How to Use the H1 Deep Transcranial Magnetic Stimulation Coil for Conditions Other than Depression

How to Use the H1 Deep Transcranial Magnetic Stimulation Coil for Conditions Other than Depression

Published on: January 23, 2017

Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research

Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research

Published on: January 5, 2024

相关概念视频

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...